Nonalcoholic Fatty Liver Disease (NAFLD) Protocol

Digestive & LiverStrong Evidence

supplements

Primary

Supporting

Grade A

120

Studies

Primary Stack

Core supplements with strongest evidence

BerberineA

500mg 2-3x daily with meals

Activates AMPK to reduce hepatic lipogenesis, improves insulin sensitivity, and directly reduces liver fat accumulation

↓Blood glucose↓Triglycerides↓Low-density lipoprotein (LDL)↑High-density lipoprotein (HDL)↓Total cholesterol

20 studies1,500 participants

Supporting Studies (2)

PMID: 25498346 - Berberine for NAFLD: meta-analysis of RCTs (2015)PMID: 29601086 - Berberine reduces hepatic steatosis and improves liver enzymes (2018)

Vitamin EA

800 IU daily (d-alpha-tocopherol)

Potent antioxidant that reduces oxidative stress and inflammation in NASH, improving histological features

All-Cause Mortality↑Liver Enzymes↓Liver Fat↓Liver Fibrosis

15 studies1,200 participants

Supporting Studies (2)

PMID: 20427778 - PIVENS trial: Vitamin E for NASH (2010)PMID: 24506596 - Vitamin E for NAFLD/NASH: meta-analysis (2014)

Supporting Stack

Additional supplements for enhanced results

Omega-3 Fatty AcidsB

2-4g EPA/DHA daily

Reduces hepatic triglyceride synthesis and inflammation; decreases liver fat content

Adiponectin↓Body Mass Index (BMI)↓Triglycerides↑Liver Enzymes↓Low-density lipoprotein (LDL)

20 studies1,500 participants

Supporting Studies (2)

PMID: 22261190 - Omega-3 for NAFLD: systematic review and meta-analysis (2012)PMID: 28410093 - Purified EPA/DHA for NAFLD: RCT (2017)

Silymarin (Milk Thistle)B

420-600mg daily (standardized to 70-80% silymarin)

Hepatoprotective flavonoid that reduces oxidative stress, inflammation, and fibrosis in the liver

15 studies1,000 participants

Supporting Studies (1)

PMID: 28946512 - Silymarin for NAFLD: systematic review (2017)

Probiotics/SynbioticsB

Multi-strain probiotic with prebiotics (synbiotic) daily

Modulates gut-liver axis, reduces endotoxemia, and improves insulin sensitivity in NAFLD

↓Blood glucose↑High-density lipoprotein (HDL)↓Insulin Resistance↑Liver Enzymes↓Low-density lipoprotein (LDL)

25 studies1,500 participants

Supporting Studies (2)

PMID: 28639228 - Probiotics for NAFLD: meta-analysis (2017)PMID: 32093831 - Synbiotics improve liver function in NAFLD (2020)

Vitamin DB

2000-4000 IU daily (target 40-60 ng/mL)

Deficiency is common in NAFLD; supplementation may improve insulin sensitivity and reduce inflammation

↓Blood glucose↑High-density lipoprotein (HDL)↓Low-density lipoprotein (LDL)↓Total cholesterol↓Triglycerides

15 studies800 participants

Supporting Studies (1)

PMID: 28571859 - Vitamin D for NAFLD: meta-analysis (2017)

ResveratrolB

500-1500mg daily

Activates SIRT1 and AMPK to reduce hepatic steatosis and inflammation

↑Adiponectin↓Body Mass Index (BMI)↓C-Reactive Protein (CRP)↑Blood Urea Nitrogen (BUN)↓Total cholesterol

10 studies500 participants

Supporting Studies (1)

PMID: 25545101 - Resveratrol for NAFLD: RCT (2015)

How This Protocol Works

Simple Explanation

Nonalcoholic fatty liver disease (NAFLD) occurs when excess fat accumulates in the liver without significant alcohol consumption. It ranges from simple fatty liver (steatosis) to nonalcoholic steatohepatitis (NASH), which involves inflammation and can progress to cirrhosis. NAFLD is strongly linked to insulin resistance, obesity, and metabolic syndrome. This protocol targets multiple pathways to reduce liver fat, inflammation, and oxidative damage.

•Berberine is one of the most effective supplements for NAFLD. It activates AMPK—a metabolic master switch that reduces the liver's production of new fat (lipogenesis) while increasing fat burning. Studies show berberine can reduce liver fat content, improve liver enzymes (ALT, AST), and enhance insulin sensitivity. It also helps with the underlying metabolic issues that cause NAFLD, including high blood sugar and elevated lipids.

•Vitamin E is the most-studied supplement for NAFLD/NASH. The landmark PIVENS trial showed high-dose vitamin E (800 IU) significantly improved liver histology in NASH patients—reducing inflammation, ballooning, and steatosis. It works by neutralizing the oxidative stress that drives liver cell damage. Note: This dose is recommended specifically for NASH; consult your doctor before starting.

•Omega-3 Fatty Acids reduce liver fat by decreasing the liver's production of triglycerides. Multiple studies show they can reduce liver fat content by 20-30% on imaging. They also have anti-inflammatory effects. Prescription omega-3s (like Lovaza) have been used in clinical trials, but high-quality fish oil provides similar EPA/DHA.

•Silymarin (Milk Thistle) has been used for liver conditions for centuries. Its active compounds (silybin, silychristin) are powerful antioxidants that protect liver cells from damage, reduce inflammation, and may even help with fibrosis. While evidence in NAFLD is still developing, it's commonly used as a liver-protective supplement with an excellent safety profile.

•Probiotics/Synbiotics address the gut-liver axis—the connection between gut bacteria and liver health. In NAFLD, gut bacteria imbalance (dysbiosis) leads to increased endotoxins that travel to the liver and trigger inflammation. Probiotics restore healthy gut bacteria, reduce endotoxemia, and improve insulin sensitivity. Synbiotics (probiotics + prebiotics) may be more effective.

•Vitamin D deficiency is very common in NAFLD patients (50-90%) and may worsen insulin resistance and inflammation. While supplementation studies show mixed results, correcting deficiency is reasonable given the strong association and vitamin D's other metabolic benefits.

•Resveratrol activates SIRT1, a protein that regulates fat metabolism and reduces liver fat accumulation. It also activates AMPK similarly to berberine. Studies show improvements in liver enzymes and inflammatory markers.

Expected timeline: Liver enzyme improvements may be seen in 4-8 weeks. Reductions in liver fat on imaging typically require 3-6 months. Lifestyle changes (weight loss, exercise, Mediterranean diet) remain the cornerstone of treatment.

Clinical Perspective

NAFLD encompasses a spectrum from simple steatosis (>5% hepatic fat) to NASH (steatosis + inflammation + hepatocellular ballooning ± fibrosis). Pathogenesis involves insulin resistance, de novo lipogenesis (DNL), oxidative stress, endoplasmic reticulum stress, mitochondrial dysfunction, and gut-derived endotoxemia. NASH can progress to cirrhosis and hepatocellular carcinoma. This protocol targets multiple mechanisms: lipogenesis inhibition, oxidative stress reduction, insulin sensitization, and gut-liver axis modulation.

•Berberine (A-grade): Activates AMPK, reducing SREBP-1c-mediated DNL and increasing fatty acid β-oxidation. Also inhibits PCSK9 (improving LDL clearance), enhances insulin receptor sensitivity via INSR upregulation, and reduces hepatic glucose output. Meta-analysis: significantly reduces ALT, AST, hepatic fat content on imaging (PMID: 25498346). RCT: 1500mg/day for 16 weeks reduced liver fat by 52% vs 36% lifestyle alone (PMID: 29601086). GI side effects common initially; may reduce metformin requirement.

•Vitamin E (A-grade): Potent lipophilic antioxidant that scavenges free radicals and inhibits lipid peroxidation—key drivers of NASH progression. PIVENS trial (N=247): 800 IU/day for 96 weeks improved histology in NASH (43% vs 19% placebo improved by ≥2 points on NAS) (PMID: 20427778). Meta-analysis confirms benefit for NASH (PMID: 24506596). AASLD guidelines recommend for non-diabetic, biopsy-proven NASH. Long-term safety at 800 IU debated; consider in appropriate patients.

•Omega-3 Fatty Acids (B-grade): EPA and DHA reduce SREBP-1c activation and hepatic VLDL secretion, decrease DNL, and increase fatty acid oxidation via PPAR-α activation. Also anti-inflammatory (resolvin/protectin synthesis). Meta-analysis: reduces hepatic steatosis on imaging and improves ALT (PMID: 22261190). RCT with purified EPA/DHA: significant liver fat reduction (PMID: 28410093). 2-4g EPA+DHA daily; prescription forms more concentrated.

•Silymarin (B-grade): Mixture of flavonolignans (silybin A/B, silychristin, silydianin) from Silybum marianum. Antioxidant (increases hepatic glutathione), anti-inflammatory (inhibits NF-κB), and antifibrotic. May also have insulin-sensitizing effects. Systematic review: improves liver enzymes, may improve histology (PMID: 28946512). 420-600mg/day; phosphatidylcholine complexes (Siliphos) improve bioavailability. Excellent safety profile.

•Probiotics/Synbiotics (B-grade): Address dysbiosis and gut-liver axis dysfunction. Reduced intestinal barrier integrity in NAFLD allows bacterial endotoxin (LPS) translocation, activating hepatic TLR4 and Kupffer cells. Probiotics (especially Lactobacillus, Bifidobacterium) reduce intestinal permeability, endotoxemia, and hepatic inflammation. Meta-analysis: improve ALT, hepatic steatosis, and some histological features (PMID: 28639228). Synbiotics (probiotics + prebiotics like inulin) may have enhanced effects (PMID: 32093831).

•Vitamin D (B-grade): VDR expressed in hepatocytes and stellate cells. Vitamin D regulates inflammatory responses, insulin signaling, and possibly fibrogenesis. Deficiency prevalent in NAFLD (50-90%) and associated with disease severity. Meta-analysis: supplementation improves insulin resistance markers; effects on liver histology less clear (PMID: 28571859). Target 40-60 ng/mL; supplement if deficient.

•Resveratrol (B-grade): Polyphenol that activates SIRT1 (deacetylates PGC-1α, increasing mitochondrial biogenesis and fat oxidation) and AMPK. Also has direct anti-inflammatory and antioxidant effects. RCT: 500mg/day for 12 weeks improved ALT, hepatic steatosis, and inflammatory markers (PMID: 25545101). Bioavailability limited; trans-resveratrol preferred.

Biomarker targets: ALT, AST (target normalization), GGT, hepatic fat fraction (MRI-PDFF, target <5%), FibroScan (CAP for steatosis, kPa for fibrosis), FIB-4 index, HbA1c, lipid panel, fasting insulin/HOMA-IR.

Protocol notes: Weight loss (7-10% body weight) is the most effective intervention—produces histological improvement in NASH. Mediterranean diet reduces hepatic fat even without weight loss. Exercise (150 min/week moderate) reduces steatosis independent of weight loss. Berberine: avoid in pregnancy; monitor if on diabetes medications. Vitamin E: limit to NASH with biopsy evidence; discuss with physician. Omega-3s: high doses may increase LDL slightly. Avoid alcohol completely. Address metabolic comorbidities (T2DM, dyslipidemia). Screen for advanced fibrosis (FIB-4, elastography); refer if elevated. Emerging therapies: GLP-1 agonists, PPAR agonists, FXR agonists under investigation.

View All Protocols